AR037350A1 - Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea) - Google Patents

Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea)

Info

Publication number
AR037350A1
AR037350A1 ARP020104332A ARP020104332A AR037350A1 AR 037350 A1 AR037350 A1 AR 037350A1 AR P020104332 A ARP020104332 A AR P020104332A AR P020104332 A ARP020104332 A AR P020104332A AR 037350 A1 AR037350 A1 AR 037350A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
nhc
heteroaryl
compounds
Prior art date
Application number
ARP020104332A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR037350A1 publication Critical patent/AR037350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

Un compuesto derivado heterocíclico que es de la fórmula (1), en la cual: R1 es fenilo (sustituido en para con: halo, hidroxi, nitro, S(O)k(alquilo C1-6), S(O)2NH2, S(O)2NH(alquilo C1-6), S(O)2N(alquilo C1-6)2, ciano, alquilo C1-6, alcoxi C1-6, NH2, NH(alquilo C1-6), N(alquilo C1-6)2, C(O)NH2, C(O)NH(alquilo C1-6), C(O)N(alquilo C1-6)2, C(O)[heterociclilo ligado a N], CO2H, CO2(alquilo C1-6), NHC(O)(alquilo C1-6), NHC(O)O(alquilo C1-6), NHS(O)2(alquilo C1-6), C(O)(alquilo C1-6), CF3, OCF3, fenilo, heteroarilo, (alquil C1-4)fenilo, (alquil C1-4) heteroarilo, NHC(O)fenilo, NHC(O)heteroarilo, NHC(O)(alquil C1-4)fenilo, NHC(O)(alquil C1-4)heteroarilo, NHS(O)2fenilo, NHS(O)2heteroarilo, NHS(O)2(alquil C1-4) fenilo, NHS(O)2(alquil C1-4)heteroarilo, NHC(O)NH(alquilo C1-6), NHC(O)NH(cicloalquilo C3-7), NHC(O)NHfenilo, NHC(O)NH heteroarilo, NHC(O)NH(alquil C1-4)fenilo ó NHC(O)NH(alquil C1-4) heteroarilo; donde los grupos fenilo y heteroarilo precedentemente mencionados están optativamente sustituidos con halo, hidroxi, nitro, S(O)k(alquilo C1-4), S(O)2NH2, S(O)2NH(alquilo C1-4), S(O)2N(alquilo C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NH(alquilo C1-4), C(O)N(alquilo C1-4)2, CO2H, CO2(alquilo C1-4), NHC(O)(alquilo C1-4), NHS(O)2(alquilo C1-4), C(O)(alquilo C1-4), CF3 ó OCF3; R2 es fenilo o heteroarilo cualquiera de los cuales está optativamente sustituido con halo, alquilo C1-4, alcoxi C1-4, S(O)n(alquilo C1-4), nitro, ciano ó CF3; R3 es hidrógeno o alquilo C1-4; R4 es etilo, alilo o ciclopropilo; R5 es hidrógeno, halógeno, hidroxi, nitro, S(O)m(alquilo C1-4), S(O)2NH2, S(O)2NH(alquilo C1-4), S(O)2N(alquilo C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NH(alquilo C1-4), C(O)N(alquilo C1-4)2, CO2H, CO2(alquilo C1-4), NHC(O)(alquilo C1-4), NHS(O)2(alquilo C1-4, C(O)(alquilo C1-4), CF3 ó OCF3; R6 es alquilo C1-4; k, m y n, independientemente 0, 1, ó 2; o una sal farmacéuticamente aceptable del mismo o un solvato del mismo; siempre que: cuando tanto R3 como R5 son hidrógeno, R4 es etilo, R6 es para -(S(O)2CH3) y R2 es fenilo no sustituido, luego R1 no sea para-metoxi-fenilo, para-metil-fenilo, para-trilfuorometil-fenilo ni 3,4-diclorofenilo; cuando tanto R3 como R5 son hidrógeno, R4 es etilo, R6 es para -(S(O)2CH3) y R2 es fenilo no sustituido, pirid-2-ilo ó pirid-4-ilo, luego R1 no sea para-cloro-fenilo y cuando tanto R3 como R5 son hidrógeno, R6 es para -(S(O)2CH3) y R2 es meta-cloro-fenilo, fenilo no sustituido o tiofen-3-ilo, luego R1 no sea para-flúor-fenilo; proceso para preparar estos compuestos, composición farmacéutica, y uso de estos compuestos para la manufactura de una medicamento útil para el tratamiento de una enfermedad mediada por CCR5 (tal como artritis reumatoidea).
ARP020104332A 2001-11-15 2002-11-12 Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea) AR037350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103819A SE0103819D0 (sv) 2001-11-15 2001-11-15 Chemical compounds

Publications (1)

Publication Number Publication Date
AR037350A1 true AR037350A1 (es) 2004-11-03

Family

ID=20286006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104332A AR037350A1 (es) 2001-11-15 2002-11-12 Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea)

Country Status (19)

Country Link
US (1) US20050014788A1 (es)
EP (1) EP1448524A1 (es)
JP (1) JP2005513017A (es)
KR (1) KR20050013526A (es)
CN (1) CN1589261A (es)
AR (1) AR037350A1 (es)
BR (1) BR0214141A (es)
CA (1) CA2464861A1 (es)
HU (1) HUP0402567A2 (es)
IL (1) IL161594A0 (es)
IS (1) IS7257A (es)
MX (1) MXPA04004497A (es)
NO (1) NO20042156L (es)
PL (1) PL370910A1 (es)
RU (1) RU2004112781A (es)
SE (1) SE0103819D0 (es)
TW (1) TW200407140A (es)
WO (1) WO2003042177A1 (es)
ZA (1) ZA200403681B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
SE0202483D0 (sv) * 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
SE0301369D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0302090D0 (sv) * 2003-07-16 2003-07-16 Astrazeneca Ab Chemical compounds
ATE361911T1 (de) * 2003-07-31 2007-06-15 Astrazeneca Ab Piperidinderivate als ccr5-rezeptormodulatoren
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
SE0303396D0 (sv) * 2003-12-16 2003-12-16 Astrazeneca Ab Chemical compounds
CN1329374C (zh) * 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
KR100905260B1 (ko) 2004-06-09 2009-06-30 상해 타킷 드러그 주식회사 씨씨알5 길항제로서의 화합물
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0403084D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Chemical process
US8354434B2 (en) 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
WO2009010478A2 (en) * 2007-07-13 2009-01-22 Euroscreen S.A. Use of piperidine derivatives as agonists of chemokine receptor activity
WO2015043713A1 (en) * 2013-09-25 2015-04-02 Merck Patent Gmbh Compounds and mesogenic media

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025686A1 (en) * 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
US20050014788A1 (en) 2005-01-20
JP2005513017A (ja) 2005-05-12
CA2464861A1 (en) 2003-05-22
MXPA04004497A (es) 2004-08-11
ZA200403681B (en) 2005-08-02
IS7257A (is) 2004-05-10
RU2004112781A (ru) 2005-10-10
PL370910A1 (en) 2005-05-30
WO2003042177A1 (en) 2003-05-22
SE0103819D0 (sv) 2001-11-15
HUP0402567A2 (hu) 2005-03-29
KR20050013526A (ko) 2005-02-04
NO20042156L (no) 2004-08-11
TW200407140A (en) 2004-05-16
BR0214141A (pt) 2004-10-19
CN1589261A (zh) 2005-03-02
WO2003042177A8 (en) 2005-01-06
EP1448524A1 (en) 2004-08-25
IL161594A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
AR037350A1 (es) Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea)
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
UY28578A1 (es) Derivados de amida
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
KR102534262B1 (ko) 헤테로환형 유도체 및 이의 용도
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR037351A1 (es) Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea) y compuestos intermediarios
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
NO20085078L (no) Nye forbindelser
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
MY143834A (en) Thrombin receptor antagonists
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
TW200616636A (en) Novel compounds
DE602004018630D1 (en) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
ES2556235T3 (es) Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist

Legal Events

Date Code Title Description
FB Suspension of granting procedure